CDX 0158

Drug Profile

CDX 0158

Alternative Names: CDX-0159; KTN 0158

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Toronto; Yale University School of Medicine
  • Developer Celldex Therapeutics Inc
  • Class Antiallergics; Antiasthmatics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Inflammation; Neurofibromatoses

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
  • 10 May 2018 Celldex plans to initiate clinical development for CDX 0159 in 2019
  • 07 Mar 2018 Celldex Therapeutics has patent protection for CDX 0158 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top